All Insights
Showing 1 - 12 of 249
Life Sciences and Healthcare
From hemp to highs: an overview of cannabis and CBD legislation across Europe
What are the key differences and overlaps across the European regulatory frameworks?
OC Ventures
From doctoral research to spin-out: a UK tech start-up's VC-backed international journey
IP, networking and seeking advice have been areas of focus for a chemical tech start-up on its path to fundraising
Regulatory Outlook
Products | UK Regulatory Outlook June 2024
UK general election 2024: product regulation aspects
UK General Election
UK general election: what are the potential implications for the life sciences and healthcare sector?
The Conservative and Labour parties both acknowledge the sector's importance to the UK's economic growth, but what plans do they
Life Sciences and Healthcare
Italy | Health and data processing for research purposes: safeguards to adopt when data subject consent cannot be obtained
A recent law has simplified procedures for conducting retrospective observational studies
Artificial intelligence
EU AI Act's 'deployers' definition has wide-ranging significance for life sciences
Identifying businesses as deployers of high-risk AI systems is crucial for understanding new regulatory responsibilities
Competition, antitrust and trade
Government updates guidance on the UK National Security and Investment Act
Changes cover call-in powers, universities and research bodies, outward direct investment and notification forms
Artificial intelligence
Low-risk AI bears high stakes for digital health in new EU regulation
Life sciences providers of low- or medium-risk AI will also be subject to the EU AI Act
Life Sciences and Healthcare
UK Medicines and Healthcare products Regulatory Agency outlines AI strategy
The MHRA has published its response on how it is aligning with the principles of the AI regulation white paper
Artificial intelligence
A new CE marking for European healthcare: when and why?
The EU AI Act's new CE-marking regime for high-risk systems has implications for life sciences and healthcare businesses
Urban Dynamics
Future Foods Update | May 2024
This edition includes new UK guidance on plant-based dairy products, an Austrian case on naming plant-based products, and EU developments
Artificial intelligence
High-risk AI systems in life sciences face strict regulatory scrutiny from new EU rules
Businesses should consider if and how AI is used internally or externally and get ready for the risk-based approach
